Comment on: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective''

被引：0
|
作者：
Liedgens, Hiltrud [1 ]
Henske, Rainer [1 ]
机构：
[1] Grunenthal GmbH, D-52099 Aachen, Germany
来源：
APPLIED HEALTH ECONOMICS AND HEALTH POLICY | 2013年 / 11卷 / 05期
关键词：
D O I：
10.1007/s40258-013-0048-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：553 / 554
页数：2
相关论文
共 50 条
  • [1] Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
    Hiltrud Liedgens
    Rainer Henske
    Applied Health Economics and Health Policy, 2013, 11 (5) : 553 - 554
  • [2] Cost-utility analysis of duloxetine in osteoarthritis: A US private payer perspective
    Wielage R.C.
    Bansal M.
    Andrews J.S.
    Klein R.W.
    Happich M.
    Applied Health Economics and Health Policy, 2013, 11 (3) : 219 - 236
  • [3] Authors' Reply to Liedgens and Henske: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective''
    Wielage, Ronald C.
    Bansal, Megha
    Andrews, J. Scott
    Klein, Robert W.
    Happich, Michael
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2013, 11 (05) : 555 - 557
  • [4] Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
    Ronald C. Wielage
    Megha Bansal
    J. Scott Andrews
    Robert W. Klein
    Michael Happich
    Applied Health Economics and Health Policy, 2013, 11 (5) : 555 - 557
  • [5] Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective
    Sun, Xueshan
    Zhen, Xuemei
    Gu, Shuyan
    Liu, Kaijie
    Yang, Wenqianzi
    Dong, Hengjin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 245 - 256
  • [6] The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective
    Liedgens, Hiltrud
    Henske, Rainer
    VALUE IN HEALTH, 2013, 16 (08) : 1172 - 1172
  • [7] The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective
    Wielage, Ronald C.
    Bansal, Megha
    Andrews, J. Scott
    Wohlreich, Madelaine M.
    Klein, Robert W.
    Happich, Michael
    VALUE IN HEALTH, 2013, 16 (02) : 334 - 344
  • [8] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [9] Peritoneal dialysis and in-centre haemodialysis: A cost-utility analysis from a UK payer perspective
    Treharne C.
    Liu F.X.
    Arici M.
    Crowe L.
    Farooqui U.
    Applied Health Economics and Health Policy, 2014, 12 (4) : 409 - 420
  • [10] A Cost-Utility Analysis of Infliximab Compared with Surgery for the Treatment of Ulcerative Colitis; A Public Payer Perspective
    Jones, Jennifer
    Worobetz, Lawrence
    Bedi, Anil
    Manns, Braden
    GASTROENTEROLOGY, 2009, 136 (05) : A172 - A172
12345